{
  "subset": "contraindication",
  "disease": "Familial tumour syndromes of the central and peripheral nervous system",
  "relation": "contraindication",
  "gold_drugs": [
    "cyproheptadine"
  ],
  "seeds_initial": [
    "Cisplatin",
    "Cyclophosphamide",
    "Doxorubicin",
    "Temozolomide",
    "Vincristine",
    "Ifosfamide",
    "Etoposide",
    "Dacarbazine",
    "Bexarotene",
    "Lomustine",
    "Carmustine",
    "Topotecan",
    "Methotrexate",
    "Gemcitabine",
    "Procarbazine",
    "Nitrosourea",
    "Thiotepa",
    "Atezolizumab",
    "Nivolumab",
    "Pembrolizumab",
    "Ipilimumab",
    "Rituximab",
    "Trastuzumab",
    "Tamoxifen",
    "Anastrozole",
    "Letrozole",
    "Aromasin",
    "Bevacizumab",
    "Erlotinib",
    "Lapatinib",
    "Sunitinib",
    "Sorafenib",
    "Tazemetostat",
    "Olaparib",
    "Rucaparib",
    "Niraparib",
    "Bortezomib",
    "Carfilzomib",
    "Dasatinib",
    "Imatinib",
    "Nilotinib",
    "Bosutinib",
    "Ponatinib",
    "Talazoparib",
    "Dexamethasone",
    "Prednisone",
    "Hydrocortisone",
    "Azathioprine",
    "Mycophenolate mofetil",
    "Sirolimus",
    "Everolimus",
    "Aminolevulinic acid",
    "Clodronate",
    "Ketorolac",
    "Ibuprofen",
    "Acetaminophen",
    "Diclofenac",
    "Celecoxib"
  ],
  "seed_history": [
    [
      "Cisplatin",
      "Cyclophosphamide",
      "Doxorubicin",
      "Temozolomide",
      "Vincristine",
      "Ifosfamide",
      "Etoposide",
      "Dacarbazine",
      "Bexarotene",
      "Lomustine",
      "Carmustine",
      "Topotecan",
      "Methotrexate",
      "Gemcitabine",
      "Procarbazine",
      "Nitrosourea",
      "Thiotepa",
      "Atezolizumab",
      "Nivolumab",
      "Pembrolizumab",
      "Ipilimumab",
      "Rituximab",
      "Trastuzumab",
      "Tamoxifen",
      "Anastrozole",
      "Letrozole",
      "Aromasin",
      "Bevacizumab",
      "Erlotinib",
      "Lapatinib",
      "Sunitinib",
      "Sorafenib",
      "Tazemetostat",
      "Olaparib",
      "Rucaparib",
      "Niraparib",
      "Bortezomib",
      "Carfilzomib",
      "Dasatinib",
      "Imatinib",
      "Nilotinib",
      "Bosutinib",
      "Ponatinib",
      "Talazoparib",
      "Dexamethasone",
      "Prednisone",
      "Hydrocortisone",
      "Azathioprine",
      "Mycophenolate mofetil",
      "Sirolimus",
      "Everolimus",
      "Aminolevulinic acid",
      "Clodronate",
      "Ketorolac",
      "Ibuprofen",
      "Acetaminophen",
      "Diclofenac",
      "Celecoxib"
    ]
  ],
  "final_report": {
    "final_recommendations": [
      {
        "hypothesis_id": "H1",
        "candidate": {
          "id": "drug_cisplatin",
          "name": "Cisplatin"
        },
        "score": 0.339,
        "graph_snapshot_ref": "GE_H1_round1",
        "key_assumptions": [
          "已知针对特定肿瘤有效",
          "安全性风险视为主要威胁"
        ],
        "caveats": [
          "高风险的副作用，未清晰风险谱"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H2",
        "candidate": {
          "id": "drug_cyclophosphamide",
          "name": "Cyclophosphamide"
        },
        "score": 0.339,
        "graph_snapshot_ref": "GE_H2_round1",
        "key_assumptions": [
          "已知针对各种肿瘤有效",
          "安全性风险视为主要威胁"
        ],
        "caveats": [
          "高风险的副作用，未清晰风险谱"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H3",
        "candidate": {
          "id": "drug_doxorubicin",
          "name": "Doxorubicin"
        },
        "score": 0.339,
        "graph_snapshot_ref": "GE_H3_round1",
        "key_assumptions": [
          "已知对几种类型的肿瘤有效",
          "安全性风险视为主要威胁"
        ],
        "caveats": [
          "高风险的副作用，未清晰风险谱"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H4",
        "candidate": {
          "id": "drug_temozolomide",
          "name": "Temozolomide"
        },
        "score": 0.339,
        "graph_snapshot_ref": "GE_H4_round1",
        "key_assumptions": [
          "已知针对特定肿瘤有效",
          "安全性风险视为主要威胁"
        ],
        "caveats": [
          "高风险的副作用，未清晰风险谱"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H5",
        "candidate": {
          "id": "drug_vincristine",
          "name": "Vincristine"
        },
        "score": 0.339,
        "graph_snapshot_ref": "GE_H5_round1",
        "key_assumptions": [
          "有效针对多种肿瘤",
          "安全性风险视为主要威胁"
        ],
        "caveats": [
          "高风险的副作用，未清晰风险谱"
        ],
        "confidence": "medium"
      }
    ],
    "audit_report": {
      "decisive_graph_motifs": [
        {
          "pattern": "Drugs → Off-target Effects → Adverse Phenotypes",
          "reason": "潜在致害通路连通性提高风险评估复杂性"
        }
      ],
      "remaining_gaps": [
        "需要进一步确认可预测的安全性特征"
      ]
    },
    "seed_retrospective": {
      "batches": [],
      "lessons": [
        "在对肿瘤标靶疗法效能的评估中，安全性风险需被重点审视与量化"
      ]
    },
    "prompt_patches": [
      {
        "role": "Proponent",
        "patch": "优先构建关于有潜在风险药物的全面效益与风险分析。"
      },
      {
        "role": "Skeptic",
        "patch": "集中分析离靶效应与对不良表现的影响。"
      }
    ],
    "heuristics": [
      {
        "when": "肿瘤药物使用",
        "then": "强调整个药物谱的安全性监控与评估方法"
      }
    ]
  }
}